LIH Study Maps Immune Suppression in Glioblastoma, Opening New Paths for Immunotherapy

LIH Study Maps Immune Suppression in Glioblastoma, Opening New Paths for Immunotherapy

(IN BRIEF) Researchers at the Luxembourg Institute of Health have published a major review in Nature Cancer proposing a new framework to explain and potentially overcome the long-standing resistance of glioblastoma to immunotherapy. The study analyses how this aggressive brain tumour systematically reshapes its immune microenvironment, suppressing effective immune responses through spatial organisation, cellular plasticity and treatment-induced remodelling. Glioblastoma is shown to be dominated by immune cells that inhibit inflammation rather than attack cancer, particularly tumour-associated macrophages that adapt dynamically to local conditions and blunt T-cell activity. Standard treatments such as radiotherapy and chemotherapy may briefly stimulate immune responses but ultimately leave behind an even more suppressive environment at recurrence. To address this, the authors introduce a temporal model distinguishing between immune priming before treatment and immune rewiring after therapy, arguing that future immunotherapies must be precisely timed and tailored to the tumour’s evolving immune state. This framework offers a new perspective that could guide the development of more effective and durable therapies for one of the most challenging cancers.

(PRESS RELEASE) LUXEMBOURG, 12-Jan-2026 — /EuropaWire/ — Scientists at the Luxembourg Institute of Health (LIH) have introduced a new conceptual framework that could help explain why immunotherapies have repeatedly failed to improve outcomes for patients with glioblastoma, one of the most aggressive and lethal forms of brain cancer. In a comprehensive review published in Nature Cancer, researchers from the NORLUX Neuro-Oncology Laboratory within LIH’s Department of Cancer Research analyse how the tumour’s immune environment is shaped, reorganised and progressively reprogrammed over time, ultimately neutralising therapeutic interventions.

Despite advances in cancer immunotherapy across multiple tumour types, glioblastoma has remained largely resistant to immune-based treatments. Even with optimal surgery followed by radiotherapy and chemotherapy, patient survival typically remains limited to little more than a year. According to the LIH researchers, a central reason for this lack of progress lies in glioblastoma’s exceptional capacity to manipulate immune cells in its surrounding microenvironment, rendering them ineffective or even supportive of tumour growth.

The review details how glioblastoma is characterised by an immunologically “cold” environment, with very few tumour-targeting T cells and a predominance of immune cells that suppress inflammation. The tumour further exploits the brain’s natural immune barriers, limiting immune cell infiltration while reorganising immune populations into distinct spatial niches defined by oxygen levels, vascular structures and tissue damage. These microenvironments strongly influence immune cell behaviour and often reinforce immune suppression rather than anti-tumour activity.

A major focus of the study is the role of tumour-associated macrophages, which can make up a substantial proportion of the tumour mass. Rather than attacking cancer cells, these macrophages are frequently reprogrammed to inhibit T-cell function and promote tumour survival. Their high degree of plasticity allows them to shift functional states in response to local conditions such as hypoxia, inflammation or treatment-induced stress, undermining therapies that target only specific immune pathways.

The researchers also examine how standard treatments reshape the immune landscape. While radiotherapy and chemotherapy may initially increase immune activation, they often leave behind a remodelled tumour environment marked by fibrosis, metabolic disruption and heightened immunosuppression. At tumour recurrence, immune cells are typically more dysfunctional than before, further limiting the impact of subsequent immunotherapies.

To address this challenge, the NORLUX team proposes a temporal framework that distinguishes between two critical phases: tumour microenvironment priming before treatment, when immune responses may be briefly enhanced, and tumour microenvironment rewiring after treatment, which requires tailored strategies to counteract therapy-induced immune suppression. By aligning therapies with these dynamic immune states, the researchers argue that future treatment strategies could finally unlock more durable immune responses against glioblastoma.

Scientific Contact
Anna Golebiewska
Group Leader, NORLUX Neuro-Oncology Laboratory

Media Contact:
Tel. : +352 26 970 893

SOURCE: LUXEMBOURG INSTITUTE OF HEALTH